Aemetis (NASDAQ:AMTX) Stock Crosses Below Two Hundred Day Moving Average of $8.80

Aemetis, Inc. (NASDAQ:AMTXGet Rating) shares crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $8.80 and traded as low as $7.60. Aemetis shares last traded at $7.63, with a volume of 557,846 shares traded.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Truist Financial lowered Aemetis from a “buy” rating to a “hold” rating and set a $12.00 price target for the company. in a report on Tuesday, August 9th. They noted that the move was a valuation call. Ascendiant Capital Markets lowered Aemetis to an “outperform” rating and set a $33.00 price target for the company. in a report on Monday, June 6th. Credit Suisse Group lowered their price objective on Aemetis from $35.00 to $27.00 and set an “outperform” rating on the stock in a research report on Monday, June 13th. Finally, StockNews.com upgraded Aemetis to a “sell” rating in a research report on Monday, September 5th.

Aemetis Price Performance

The company has a market cap of $263.88 million, a price-to-earnings ratio of -6.75 and a beta of 0.54. The business has a 50 day simple moving average of $8.17 and a 200 day simple moving average of $8.80.

Aemetis (NASDAQ:AMTXGet Rating) last posted its quarterly earnings data on Thursday, August 4th. The specialty chemicals company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.40. The business had revenue of $65.90 million during the quarter, compared to analyst estimates of $61.73 million. During the same period in the prior year, the firm posted ($0.38) EPS. As a group, sell-side analysts anticipate that Aemetis, Inc. will post -1.61 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aemetis

Large investors have recently made changes to their positions in the company. BNP Paribas Arbitrage SA lifted its stake in shares of Aemetis by 61.6% during the fourth quarter. BNP Paribas Arbitrage SA now owns 11,355 shares of the specialty chemicals company’s stock valued at $140,000 after acquiring an additional 4,328 shares during the period. Evercore Wealth Management LLC lifted its stake in shares of Aemetis by 40.0% during the fourth quarter. Evercore Wealth Management LLC now owns 70,000 shares of the specialty chemicals company’s stock valued at $861,000 after acquiring an additional 20,000 shares during the period. Greenleaf Trust acquired a new position in shares of Aemetis during the first quarter valued at $139,000. L & S Advisors Inc lifted its stake in shares of Aemetis by 42.6% during the first quarter. L & S Advisors Inc now owns 138,404 shares of the specialty chemicals company’s stock valued at $1,754,000 after acquiring an additional 41,316 shares during the period. Finally, Capital Fund Management S.A. acquired a new position in shares of Aemetis during the first quarter valued at $302,000. Institutional investors and hedge funds own 51.91% of the company’s stock.

Aemetis Company Profile

(Get Rating)

Aemetis, Inc operates as a renewable natural gas and renewable fuels company in North America and India. It operates through three segments: California Ethanol, Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the acquisition, development, and commercialization of negative carbon intensity products and technologies that replace traditional petroleum-based products.

Featured Stories

Receive News & Ratings for Aemetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aemetis and related companies with MarketBeat.com's FREE daily email newsletter.